Sareum Holdings plc (LON:SAR – Get Free Report)’s share price traded up 1.9% during mid-day trading on Monday . The company traded as high as GBX 27 ($0.34) and last traded at GBX 27 ($0.34). 264,022 shares changed hands during mid-day trading, a decline of 61% from the average session volume of 674,550 shares. The stock had previously closed at GBX 26.50 ($0.33).
Sareum Stock Up 1.2 %
The stock has a market capitalization of £29.49 million, a PE ratio of -466.50 and a beta of -1.08. The business’s fifty day moving average is GBX 26.23 and its 200-day moving average is GBX 30.35.
About Sareum
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases.
Read More
- Five stocks we like better than Sareum
- Investing in the High PE Growth Stocks
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Stock Analyst Ratings and Canadian Analyst Ratings
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
